Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 9/20 | 0.38 |
| ▸ | FGF1 | P05230 | 5/20 | 0.38 |
| ▸ | FGF2 | P09038 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | BDNF | P23560 | 3/20 | 0.36 |
| ▸ | PTN | P21246 | 2/20 | 0.36 |
| ▸ | MDK | P21741 | 2/20 | 0.36 |
| ▸ | VEGFA | P15692 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17167215 | 0.90 | MAPK1 (0.47) | HPSEFGF1FGF2MAPK1BDNF | |
| SCHEMBL17167195 | 0.89 | F10 (0.51) | HPSEFGF1FGF2F10BDNF | |
| SCHEMBL18915088 | 0.84 | HPSE (0.44) | HPSEFGF1FGF2MAPK1BDNF | |
| SCHEMBL17167191 | 0.81 | MDK (0.56) | HPSEFGF1FGF2MAPK1F10 | |
| SCHEMBL17167261 | 0.79 | MDK (0.45) | HPSEFGF1FGF2F10BDNF | |
| SCHEMBL17167673 | 0.76 | HPSE (0.38) | HPSEFGF1FGF2MAPK1BDNF | |
| SCHEMBL18915089 | 0.76 | MDK (0.49) | HPSEFGF1FGF2F10BDNF | |
| SCHEMBL17167255 | 0.75 | F10 (0.44) | HPSEFGF1FGF2F10BDNF | |
| SCHEMBL17167718 | 0.75 | HPSE (0.36) | HPSEFGF1FGF2BDNFPTN | |
| SCHEMBL17167832 | 0.75 | HPSE (0.36) | HPSEFGF1FGF2BDNFPTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152279-A9 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | UNIVERSITY OF LIVERPOOL (GB) | 2017-06-01 | — | — | US | disclosed |
| US-20150291644-A1 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | VICTORIA LINK LTD (NZ) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291644-A1 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | BACE1, BACE2, APP | HPSE 134/4885FGF1 1768/4885FGF2 2224/4885 |
| US-20170152279-A9 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | BACE1, BACE2, APP | HPSE 134/4885FGF1 1768/4885FGF2 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.